Skip to main content

Table 1 Baseline characteristics of patients in cohorts C1–C4 (N = 1275)

From: Switching first-line targeted therapy after not reaching low disease activity within 6 months is superior to conservative approach: a propensity score-matched analysis from the ATTRA registry

 

C1 (n = 62)

C2 (n = 598)

C3 (n = 124)

C4 (n = 491)

Female, n (%)

52 (83.9%)

431 (72.1%)

102 (82.3%)

390 (79.4%)

Age at diagnosis, years, median (IQR)

44.0 (34.0–52.0)

43.5 (33.0–52.0)

45.0 (34.0–51.5)

47.0 (38.0–54.0)

Age at start of 1st line, years, median (IQR)

51.0 (42.0–58.0)

53.0 (41.0–60.0)

52.0 (44.5–61.0)

55.0 (48.0–63.0)

Disease duration, years, median (IQR)

5.6 (3.0–7.8)

6.0 (2.5–11.8)

5.0 (2.2–12.1)

6.2 (3.0–12.9)

RF positive, n (%)

47 (75.8%)

428 (71.6%)

92 (74.2%)

389 (79.6%)

ACPA positive, n/total (%)

44/61 (72.1%)

399/587 (68.0%)

91/120 (75.8%)

348/480 (72.5%)

Presence of erosions, n/total (%)

25/38 (65.8%)

210/295 (71.2%)

46/67 (68.7%)

22/290 (76.6%)

Currently smoking, n/total (%)

10/53 (18.9%)

102/504 (20.2%)

26/103 (25.2%)

93/413 (22.5%)

Number of previous csDMARDs, n (%)

 0

0 (0.0%)

8/592 (1.4%)

2 (1.6%)

6/484 (1.2%)

 1

13 (21.0%)

226/592 (38.2%)

27 (21.8%)

131/484 (27.1%)

 2

18 (29.0%)

147/592 (24.8%)

30 (24.2%)

165/484 (34.1%)

 3

17 (27.4%)

112/592 (18.9%)

35 (28.2%)

113/484 (23.3%)

 4+

14 (22.6%)

99/592 (16.7%)

30 (24.2%)

69/484 (14.3%)

Glucocorticoids in previous history, n (%)

56 (90.3%)

519/597 (86.9%)

112 (90.3%)

442 (90.0%)

Concomitant csDMARDs, n (%)

54 (87.1%)

549 (91.8%)

107 (86.3%)

440 (89.6%)

Concomitant MTX, n (%)

44 (71.0%)

454 (75.9%)

77 (62.1%)

349 (71.1%)

Concomitant GCs, n (%)

49 (79.0%)

446 (74.6%)

96 (77.4%)

402 (81.9%)

DAS28-ESR (0–10), median (IQR)

6.4 (5.7–7.0)

5.9 (5.3–6.5)

6.2 (5.6–6.8)

6.3 (5.8–6.8)

TJC (28 joints), median (IQR)

14.0 (11.0–19.0)

12.0 (9.0–16.0)

14.5 (9.0–19.0)

13.0 (10.0–18.0)

SJC (28 joints), median (IQR)

10.0 (7.0–13.0)

9.0 (6.0–12.0)

9.5 (6.0–12.5)

10.0 (7.0–13.0)

ESR (mm/h), median (IQR)a

33.5 (16.0–53.0)

28.0 (16.0–40.0)

32.0 (18.0–50.0)

34.0 (23.0–50.0)

CRP (mg/l), median (IQR)b

22.0 (9.4–34.0)

12.0 (5.3–23.5)

15.0 (7.9–31.0)

16.8 (8.0–33.1)

SDAI (0–86), median (IQR)c

40.5 (32.7–47.8)

35.6 (29.5–42.4)

39.3 (33.0–48.2)

39.0 (32.6–45.9)

PTGA (0–100), median (IQR)

78.0 (69.0–84.0)

70.0 (59.0–80.0)

75.0 (62.5–81.5)

75.0 (60.0–85.0)

MDGA (0–100), median (IQR)d

74.0 (60.0–80.0)

65.0 (52.0–75.0)

70.0 (58.5–80.0)

70.0 (60.0–80.0)

HAQ-DI (0–3), median (IQR)

1.8 (1.3–2.0)

1.4 (1.0–1.8)

1.8 (1.4–2.0)

1.8 (1.4–2.0)

EQ-5D (− 0.59–1), median (IQR)

0.1 (0.0–0.6)

0.2 (0.1–0.7)

0.1 (0.0–0.5)

0.1 (0.0–0.5)

  1. IQR interquartile range, RF rheumatoid factor, ACPA anti-citrullinated protein, TNFi tumour necrosis factor inhibitor, csDMARDs conventional synthetic disease-modifying anti-rheumatic drugs, MTX methotrexate, DAS28-ESR 28-joint disease activity score with ESR, TJC tender joint count, SJC swollen joint count, ESR erythrocyte sedimentation rate, CRP C-reactive protein, SDAI Simplified Disease Activity Index, PTGA patient general assessment of disease activity, MDGA physician general assessment of disease activity, HAQ-DI Health Assessment Questionnaire, EQ-5D EuroQol 5 Dimension for measuring the quality of life
  2. an = 62 (C1), n = 573 (C2), n = 118 (C3), n = 486 (C4)
  3. bn = 60 (C1), n = 576 (C2), n = 123 (C3), n = 480 (C4)
  4. cn = 55 (C1), n = 560 (C2), n = 119 (C3), n = 465 (C4)
  5. dn = 57 (C1), n = 582 (C2), n = 120 (C3), n = 476 (C4)
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us